R

Refeyn

Bench-top mass photometry for single molecules

Key Account Manager

Full-Time
$130k - $160k/yr+ Up to 40% bonus + 5% 401(k) match
Mid
Bachelor's, Master's, PhD
San Francisco, CA, USA
Remote
Sales & Account ManagementAccount Management

About the job

Requirements
  • A Bachelor of Science or Master's degree in biochemistry, molecular biology, biophysics, or another relevant subject is required.
  • Extensive experience selling scientific capital equipment or analytical instruments in research and development environments is required.
  • Experience selling into the Good Manufacturing Practice and bioprocessing market is required, including supporting customers validating new technologies and organizations involved in clinical development and clinical trials.
  • Advanced knowledge of selling strategies and methods, including consultative sales and sales profiling frameworks, is required.
  • Advanced knowledge of Customer Relationship Management systems, specifically Salesforce, is required.
  • Completion of at least three planning cycles for a market or customer group is required.
  • Experience creating and executing tactical sales plans is required.
  • A record of owning and consistently achieving or exceeding targets is required.
  • Demonstrable experience hunting and creating new business is required.
  • Experience pitching successfully to key stakeholders is required.
  • Experience leading successful negotiations with key accounts is required.
  • Experience communicating with different audiences and cross-functional teams is required.
  • Strong organizational and time management skills are required.
  • Experience working remotely and autonomously is required.
  • Hands-on experience with a variety of bioanalytical techniques is required.
  • Experience with ERM and CRP management is required.
  • Experience with channel partner management is required.
Responsibilities
  • Develop and manage mutually beneficial partnerships between Refeyn and named key accounts within the designated territory.
  • Work with technical sales support teams and regional sales leaders globally to drive the development of named accounts.
  • Build account profiles for named accounts, including global sites, site functions, key personnel, biophysical characterization tools and technologies, and connections between sites.
  • Record account business intelligence using appropriate business tools.
  • Develop a deep understanding of client requirements and build relationships with individuals at sites within and beyond the territory.
  • Develop solutions, products, and services with clients at key accounts in ways that benefit both businesses and their clients.
  • Maintain regular contact between key accounts and the Refeyn team to ensure customer success with current and future product and service installations.
  • Serve as the main communication channel between Refeyn and key accounts for Marketing, Sales, Customer Support, Product Development, and Management.
  • Develop long-term account-retention strategies, prevent competitor penetration, and ensure opportunities across global accounts are characterized and captured in the Customer Relationship Management system.
  • Prepare and present regular key-account updates to internal Refeyn stakeholders.
Desired Qualifications
  • A PhD in biochemistry, molecular biology, biophysics, or another relevant subject is advantageous.
  • Experience coaching or mentoring a more junior team member.
  • Potential to be developed into a leader at the same level.
  • An established customer network for the relevant market or customer groups is preferable.

About the company

Refeyn specializes in mass photometry, a technique that measures the mass of single molecules in their native, unlabeled state. Its products are compact bench-top instruments coupled with automated software that enables rapid mass analysis from only a few microliters of sample. Researchers can obtain mass distributions in minutes without prior knowledge or labeling. The company differentiates itself through its native-state, label-free approach, user-friendly bench-top systems, and integrated software that streamlines data acquisition and interpretation, making advanced biomolecule analysis accessible to academic labs, research centers, and pharmaceutical companies. Refeyn aims to advance bioanalytics by providing practical mass measurement tools that uncover biomolecular properties and functions with minimal setup and sample requirements.

Company Size

51-200

Company Stage

Series A

Total Funding

$30M

Headquarters

Oxford, United Kingdom

Founded

2018

Get referred to Refeyn

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Refeyn won the Sunday Times 100 Tech ranking in January 2026.
  • Refeyn launched MyMassMP on March 18, 2026 and expanded CRO/CDMO channels.
  • Refeyn reached 1,000-plus publications and opened Waltham HQ, deepening U.S. access.

What critics are saying

  • Thermo Fisher and Bruker can bundle broader proteomics platforms faster than Refeyn.
  • Refeyn still depends on niche adoption; 500 installations by May 2025 stays tiny.
  • If MyMass and TwoMP sales stall, Oxford hardware economics and hiring plans weaken.

What makes Refeyn unique

  • Mass photometry measures single molecules label-free, native-state, using microliters and minutes.
  • Refeyn's 2026 MyMass product simplifies sample-quality checks before cryo-EM, native MS, SPR, BLI.
  • Bio-Techne's June 2026 workflow integrates TwoMP into bispecific-antibody characterization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Company Match
  • Unlimited Paid Time Off
  • Family Planning Benefits
  • Professional Development Budget
  • Hybrid Work Options
  • Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
Yahoo Finance
Jun 4th, 2026
Bio-Techne and Refeyn close gap in bispecific antibody characterisation with 4-hour workflow

Bio-Techne and Refeyn have launched an integrated workflow combining icIEF fractionation and mass photometry to characterise bispecific antibodies and biosimilars. The four-hour process pairs Bio-Techne's MauriceFlex imaged capillary isoelectric focusing system with Refeyn's TwoMP mass photometry platform. The workflow enables direct correlation of charge heterogeneity with molecular weight and aggregation at single-molecule resolution, requiring only nanogram-level samples. This addresses a key challenge in characterising bispecific antibodies, whose structural complexity often delays development and increases manufacturing risk. The technology allows researchers to analyse aggregation and size within icIEF-resolved charge variants, providing insights previously inaccessible with standalone methods. The integration aims to reduce reliance on multiple tests and accelerate process development for increasingly complex biologics.

Financial Post
Mar 18th, 2026
Refeyn launches MyMass instrument to simplify sample quality assessment for structural biology.

Refeyn launches MyMass instrument to simplify sample quality assessment for structural biology. GlobeNewswire Published Mar 18, 2026 Article content Compact, all-in-one mass photometer helps researchers verify sample quality before proceeding to cryo-EM, native MS, BLI, SPR, and other costly experiments Article content OXFORD, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) - Refeyn, developer of pioneering mass photometry technology, announces the launch of MyMass(TM) mass photometer (MyMassMP), a compact instrument designed to answer a critical research question: Is the sample good enough for further analysis? Article content Structure-based drug design and AI-driven therapeutic development are transforming how new medicines are discovered, but depend on high-quality samples. Structural and biophysical workflows, such as cryo-EM, native mass spectrometry (MS), bio-layer interferometry (BLI), and surface plasmon resonance (SPR), are time-consuming and costly, and poor sample quality remains one of the main reasons they fail. MyMassMP gives researchers a fast, accurate assessment of purity, homogeneity, and oligomerization state in solution before committing to resource-intensive experiments. Article content Advertisement 1 Story continues below Article content Built on the same proven technology as Refeyn's TwoMP mass photometer, which is already trusted across leading structural biology and biotherapeutics labs worldwide, MyMassMP brings this quality check capability into a simpler, self-contained benchtop instrument. Featuring an integrated display and computer for onboard data analysis, and dedicated consumables, it offers an intuitive workflow from sample to result. Article content Top Stories Interested in more newsletters? Browse here. Article content "Structural biology and AI-driven drug discovery are moving fast, but they're only as good as the samples that drive them. MyMass directly addresses that challenge and marks a significant step forward for Refeyn, putting the power of mass photometry within reach of more researchers than ever before," said Gerry Mackay, Refeyn CEO. Article content Fiona Coats, Chief Product and Marketing Officer at Refeyn, said: "In recent years, our users have consistently shown us how valuable mass photometry is for quickly assessing sample quality before committing to more complex experiments. With MyMassMP, we're making this capability even more accessible - empowering researchers to confidently answer a simple but critical question: Are my samples ready?" Article content Advertisement 2 Story continues below Article content About Refeyn Article content Refeyn (www.refeyn.com) specializes in the development, production, and distribution of mass photometry for industry and academia. Enabling accurate mass measurement of single molecules in their native state, and without labels, Refeyn's products deliver crucial analytics faster and use less sample than conventional methods. The company's vision is to accelerate discovery through innovation, empowering the latest scientific breakthroughs in basic research and transforming biotherapeutic development and manufacturing. Article content Advertisement 1 This advertisement has not loaded yet.

PharmiWeb
May 7th, 2025
Major Mass Photometry Milestone Achieved By Refeyn With 500Th Installation Globally

Over 1,000 scientific citations highlight the unique bioanalytical workflow capabilities of mass photometry systems now installed in 30+ countries. Refeyn’s TwoMP mass photometer and MassFluidix HC system newly installed at the University of Copenhagen in action with Dr. Anni Kumari. For a high-resolution image, please contact [email protected]

Taylor & Francis
Dec 4th, 2024
Biotech bi-weekly: New bioink for light-based bioprinting, evolving software for drug discovery, mass photometry and multiomics data analysis

Refeyn (Oxford, UK), a mass photometry technology company, has developed a custom software platform providing automated analysis of large mass photometry data, called StreamlineMP.

PharmiWeb
Nov 26th, 2024
Refeyn Launches Software Platform To Automate Mass Photometry Analysis Workflows

Refeyn launches software platform to automate mass photometry analysis workflows. New StreamlineMP software suite offers specialized data analysis modules to standardize and speed up workflows in key bioanalytical applications